USPTO serial 90332957
AKOUOS
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Mar 12, 2024
- Examiner
- YONTEF, DAVID ERIC
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with AKOUOS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Bruce W. Longbottom
Lilly Corporate CenterIndianapolis, IN 42685UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; biologics and small molecules both in the nature of pharmaceutical preparations for the treatment of genetically-related inner ear diseases and conditions causing hearing loss; gene therapy products to restore, improve and preserve hearing, namely, genetically engineered tissues for inner ear transplant purposes and drug delivery agents for use in the inner ear consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; gene therapy products, namely, biological preparations for the treatment of inner ear disorders and conditions; viral vectors, non-viral vectors and gene therapy vectors all for medical purposes, namely, therapeutic agents for delivering nucleic acid and other genetic material to nuclei of targeted cells in the human body, for use in gene therapy to treat inner ear disorders and conditions; biotechnological platform technology for gene delivery to biological cells, namely, biological nanoparticles and adenoviruses featuring adeno-associated viral (AAV) vectors therein to provide platforms for specific expressions of biologics with therapeutic effects in gene therapy, all to restore, improve and preserve hearing; biotechnological platform technology for gene delivery to biological cells, namely, biological nanoparticles and adenoviruses featuring adeno-associated viral (AAV) vectors therein to provide platforms for specific expressions of biologics with therapeutic effects in gene therapy, all to treat inner ear disorders and conditions | ACTIVE | Nov 22, 2023 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 12, 2024 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Mar 12, 2024 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Feb 3, 2024 | SUNA | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | — |
| Feb 2, 2024 | CNPR | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | — |
| Feb 1, 2024 | SUPC | STATEMENT OF USE PROCESSING COMPLETE | — |
| Feb 1, 2024 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Jan 11, 2024 | IUAF | USE AMENDMENT FILED | — |
| Jan 11, 2024 | EISU | TEAS STATEMENT OF USE RECEIVED | The applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action. |
| Sep 13, 2023 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Sep 13, 2023 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 13, 2023 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Sep 13, 2023 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Sep 13, 2023 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Aug 4, 2023 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Aug 3, 2023 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Aug 2, 2023 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Aug 2, 2023 | EXT4 | SOU EXTENSION 4 FILED | — |
| Aug 2, 2023 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Feb 9, 2023 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Feb 7, 2023 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Feb 7, 2023 | EXT3 | SOU EXTENSION 3 FILED | — |
| Feb 7, 2023 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Aug 11, 2022 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Aug 9, 2022 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Aug 9, 2022 | EXT2 | SOU EXTENSION 2 FILED | — |
| Aug 9, 2022 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Feb 10, 2022 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Feb 8, 2022 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Feb 8, 2022 | EXT1 | SOU EXTENSION 1 FILED | — |
| Feb 8, 2022 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Aug 10, 2021 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jun 15, 2021 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jun 15, 2021 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| May 26, 2021 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| May 11, 2021 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 11, 2021 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| May 11, 2021 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| May 11, 2021 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| May 11, 2021 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| May 11, 2021 | AMPX | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED | — |
| May 7, 2021 | PARI | TEAS VOLUNTARY AMENDMENT RECEIVED | — |
| May 4, 2021 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 27, 2021 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Jan 26, 2021 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Nov 24, 2020 | NWAP | NEW APPLICATION ENTERED | — |